Stroke in Patients With Unresectable Pancreatic Cancer Undergoing Chemotherapy: Clinical Characteristics and Risk Assessment.
코호트
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
11 patients (3.
I · Intervention 중재 / 시술
anticoagulants and/or mechanical thrombectomy, only 2 patients were able to continue chemotherapy after the stroke
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Stroke within 180 days occurred in 3.2% of patients and was commonly associated with discontinuation of chemotherapy and short survival. The combined score calculated with D-dimer and CA 19-9 levels predicted the stroke risk in pancreatic cancer patients receiving chemotherapy.
[OBJECTIVES] Ischemic stroke is one of the most serious complications in pancreatic cancer patients.
- 연구 설계 cohort study
APA
Hata A, Ueno M, et al. (2026). Stroke in Patients With Unresectable Pancreatic Cancer Undergoing Chemotherapy: Clinical Characteristics and Risk Assessment.. Pancreas, 55(2), e173-e180. https://doi.org/10.1097/MPA.0000000000002555
MLA
Hata A, et al.. "Stroke in Patients With Unresectable Pancreatic Cancer Undergoing Chemotherapy: Clinical Characteristics and Risk Assessment.." Pancreas, vol. 55, no. 2, 2026, pp. e173-e180.
PMID
40815799 ↗
Abstract 한글 요약
[OBJECTIVES] Ischemic stroke is one of the most serious complications in pancreatic cancer patients. In this study, we examined the clinical characteristics and risk factors for stroke in patients with unresectable pancreatic cancer receiving chemotherapy.
[MATERIALS AND METHODS] We conducted a retrospective cohort study of 343 consecutive patients with recurrent or unresectable pancreatic cancer with chemotherapy started between April 2017 and December 2022. We investigated the clinical characteristics of stroke and risk factors for stroke within 180 days after starting chemotherapy and during the entire follow-up period.
[RESULTS] Stroke occurred in 11 patients (3.2%) within the first 180 days. Although 5 patients were treated with anticoagulants and/or mechanical thrombectomy, only 2 patients were able to continue chemotherapy after the stroke. The median survival time after stroke was 28 days. Elevated D-dimer (≥2.9 μg/mL) and CA19-9 (≥1621 U/mL) values at the start of chemotherapy were significant independent risk factors for stroke within 180 days. The combined score calculated with these 2 factors stratified the stroke risk within 180 days and during the entire follow-up period of a median of 11.3 months and as long as 58.7 months.
[CONCLUSIONS] Stroke within 180 days occurred in 3.2% of patients and was commonly associated with discontinuation of chemotherapy and short survival. The combined score calculated with D-dimer and CA 19-9 levels predicted the stroke risk in pancreatic cancer patients receiving chemotherapy.
[MATERIALS AND METHODS] We conducted a retrospective cohort study of 343 consecutive patients with recurrent or unresectable pancreatic cancer with chemotherapy started between April 2017 and December 2022. We investigated the clinical characteristics of stroke and risk factors for stroke within 180 days after starting chemotherapy and during the entire follow-up period.
[RESULTS] Stroke occurred in 11 patients (3.2%) within the first 180 days. Although 5 patients were treated with anticoagulants and/or mechanical thrombectomy, only 2 patients were able to continue chemotherapy after the stroke. The median survival time after stroke was 28 days. Elevated D-dimer (≥2.9 μg/mL) and CA19-9 (≥1621 U/mL) values at the start of chemotherapy were significant independent risk factors for stroke within 180 days. The combined score calculated with these 2 factors stratified the stroke risk within 180 days and during the entire follow-up period of a median of 11.3 months and as long as 58.7 months.
[CONCLUSIONS] Stroke within 180 days occurred in 3.2% of patients and was commonly associated with discontinuation of chemotherapy and short survival. The combined score calculated with D-dimer and CA 19-9 levels predicted the stroke risk in pancreatic cancer patients receiving chemotherapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
- Humans
- Pancreatic Neoplasms
- Male
- Female
- Retrospective Studies
- Aged
- Middle Aged
- Risk Factors
- Risk Assessment
- Fibrin Fibrinogen Degradation Products
- Stroke
- 80 and over
- CA-19-9 Antigen
- Ischemic Stroke
- Antineoplastic Combined Chemotherapy Protocols
- CA19-9
- D-dimer
- cancer-associated thrombosis
- ischemic stroke
- pancreatic cancer
같은 제1저자의 인용 많은 논문 (2)
- Wedge resection versus segmentectomy in peripheral clinical stage IA lung cancer concerning ground-glass opacity.
- Radiotherapy-free pembrolizumab combined with chemotherapy for locally advanced non-small-cell lung cancer with PD-L1 tumour proportion score of 50% or higher (Evolution trial): a multicentre, single-arm, phase 2 study.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.